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ABSTRACT
Background. The ﬁnancial burden of chronic kidney disease
(CKD) is increasing due to the ageing population and increased
prevalence of comorbid diseases. Our aim was to evaluate age-
related differences in health care use and costs in Stage G4/G5
CKD without renal replacement therapy (RRT), dialysis and
kidney transplant patients and compare them to the general
population.
Methods. Using Dutch health care claims, we identiﬁed CKD
patients and divided them into three groups: CKD Stage G4/G5
without RRT, dialysis and kidney transplantation. We matched
them with two controls per patient. Total health care costs and
hospital costs unrelated to CKD treatment are presented in four
age categories (19–44, 45–64, 65–74 and75 years).
Results.Overall, health care costs of CKD patients75 years of
age were lower than costs of patients 65–74 years of age. In dial-
ysis patients, costs were highest in patients 45–64 years of age.
Since costs of controls increased gradually with age, the cost ra-
tio of patients versus controls was highest in young patients
(19–44 years). CKD patients were in greater need of additional
specialist care than the general population, which was already
evident in young patients.
Conclusion. Already at a young age and in the earlier stages of
CKD, patients are in need of additional care with corresponding
health care costs far exceeding those of the general population.
In contrast to the general population, the oldest patients
(75 years) of all CKD patient groups have lower costs than
patients 65–74 years of age, which is largely explained by lower
hospital and medication costs.
Keywords: chronic kidney disease, costs, dialysis, health
claims data, kidney transplantation
INTRODUCTION
Patients with chronic kidney disease (CKD), including those
needing renal replacement therapy (RRT), contribute signifi-
cantly to health care expenditures [1–5]. The prevalence of
CKD is increasing as a result of both population ageing and the
increasing prevalence of diseases like hypertension and diabetes
mellitus. Therefore the financial burden for society is also likely
to increase substantially [6–8].
Important factors affecting the high health care costs of
patients with CKD include specific renal treatment costs and
the fact that a significant number of patients need additional
care for their CKD-related comorbid conditions [9].
Nevertheless, it is largely unknown how many patients need
additional care and for which diagnosis this additional care
is needed. Since studies have shown that the prevalence of
comorbidities in young patients is lower than in the elderly
and that the burden of comorbidities in CKD patients
increases with age, attention has mainly been drawn to the
clinical management of elderly CKD patients. However, the
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impact of age on health care use and costs of CKD-related
comorbidities has rarely been studied [10, 11].
Better knowledge of the age-related differences in health
care use and costs leads to a better understanding of the impact
of comorbidities on CKD patients in different age categories
and will potentially lead to improved, age-specific, clinical man-
agement of CKD patients. Furthermore, a comparison with
care delivered to individuals of similar age in the general popu-
lation is needed to gain insights into the extra care provided to
CKD patients and the additional costs. Therefore the aim of
this study was to assess the age-related differences in health care
use and costs of patients with advanced CKD (Stage G4/G5)
without RRT, on dialysis and kidney transplant patients and to
compare the results with the general population.
MATERIALS AND METHODS
Data
To identify renal patients and to study health care costs, we
used Dutch health care claims from 2016. These claims are re-
lated to all health care procedures covered by the Health
Insurance Act, including the costs of compulsory co-payments
[12]. The Vektis database contains health care claims and de-
mographic data from all health insurance companies in the
Netherlands. The database covers 99% of all insured residents,
and since health care insurance is obligatory in the
Netherlands, almost all Dutch residents are insured (99%).
Demographic data include year of birth, sex, postal code and
date of death, if applicable. A person’s socio-economic status
(SES) was determined by the Netherlands Institute for Social
Research and was based on a person’s postal code [13]. The SES
score is a reflection of the mean income, the education and the
position in the labour market of people living in a postal code
area. The mean SES score has been set at 0 and ranges from
6.75 to 3.06; lower scores indicating a lower SES and higher
scores indicating a higher SES. To ensure privacy, Vektis pseu-
donymized the persons’ national identification number and
allowed data access only in a secured environment.
Study population
We selected adult patients (i.e. 20 years of age) with ad-
vanced CKD [Stage G4 with an estimated glomerular filtration
rate (eGFR) of 15–29mL/min/1.73m2 and Stage G5 with an
eGFR 15mL/min/1.73m2] with or without RRT using health
care claims in the year 2016 and who were alive and insured
during the whole year. Patients with incomplete data on year
of birth or sex were excluded from the analysis. Patients
were divided into four age categories: young (20–44 years),
middle-aged (45–64 years), elderly (65–74 years) and 75 years
of age.
CKD patients were divided into three groups: CKD
Stage G4/G5 patients without RRT, CKD patients with dialysis
treatment and CKD patients with a kidney transplantation.
A detailed list of all diagnosis-related groups (DRGs) used
for allocation to groups is provided in Supplementary data,
Table S1.
CKD Stage G4/G5. We selected patients with CKD Stage
G4/G5 not treated with RRT. In the Netherlands, DRGs are
based on health care claims of specialist care delivered in the
hospital. Primary care has no comparable disease-specific
health care claims. Hence we were unable to identify patients
with CKD Stage G4/G5 treated solely in primary care. Patients
with health claims for dialysis or kidney transplantation and
those who died in the same year were excluded from this group.
Dialysis. We selected CKD patients who were on dialysis
treatment in 2016 for the entire year regardless of their dialysis
modality. Patients who started dialysis, received a kidney trans-
plant or died in 2016 were excluded. Analyses were performed
for the whole dialysis group and separately for haemodialysis
and peritoneal dialysis.
Kidney transplantation. We selected CKD patients with a
health claim for a new kidney transplantation or for follow-up
care after a kidney transplantation during 2016. We excluded
transplant patients who started dialysis or died in 2016.
Controls. For every patient in each patient group, we ran-
domly selected two controls, matched for age, sex and SES score
(four groups based on quartiles). Controls were randomly se-
lected out of the entire Vektis database, provided they had no
health care claim for CKD. In both cases and controls, patients
of90 years of age were clustered.
Cost variables
The Vektis data contain DRG claims related to the use of
health care resources. As DRG claims are based on negotiated
administrative prices for high-level groups of diagnoses, the
expenses are an approximation of the real costs. For ease of ref-
erence, we will refer to these expenses as ‘costs’. Costs were
expressed per calendar year. The total annual costs consisted of
all costs reimbursed through health insurance in a year.
Total health care costs encompassed costs of primary care,
specialist care delivered in the hospital (inpatient and outpa-
tient), mental health care, prescription medication (excluding
medication administered in a hospital and during dialysis treat-
ment, as these are covered by the respective hospital DRGs),
transportation and other costs. It should be noted that, in the
Netherlands, some prescribed drugs need (co-)payment by the
patient. A patient’s costs for drugs not covered by the health
care system (including over-the-counter drugs) are not in-
cluded in the health claims database and are therefore not cov-
ered in our study. Hospital costs are based on DRG claims: the
reimbursement of a DRG is a negotiated price covering all costs
related to the diagnosis and treatment, including, for example,
all laboratory assessments and other diagnostics (e.g. chest X-
ray, echocardiographs or electrocardiograms).
Hospital costs related to CKD included the costs of all DRG
claims for nephrological inpatient and outpatient care, costs of
dialysis (including access surgery and maintenance) and the
costs of renal transplant care (including the costs for transplant
surgery). Moreover, these DRGs encompassed costs for hospital
admission related to CKD, medication administered in the
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hospital and during dialysis treatment, staff costs (such as phy-
sician fees) and diagnostic procedures related to CKD.
Hospital costs unrelated to CKD were all other inpatient and
outpatient DRG costs. Since DRGs are categorized by medical
specialty, we were able to categorize hospital costs into the costs
related to consultation of internists, cardiologists, dermatolo-
gists and surgeons, as these four medical specialties are of spe-
cial importance to CKD patients. In the Netherlands, specialist
consultation is carried out in a hospital (inpatient or outpatient
care) and therefore all specialist care costs were included in this
study. Costs were estimated by calculating the average costs of
all DRG claims assigned to the specified medical specialties.
Within the groups of specialist care, we analysed the most fre-
quently claimed DRG codes per year.
Statistical analysis
We used descriptive statistics to examine the characteristics
of the patient groups and their matched controls in four age cat-
egories. The average annual costs are presented as mean per
person with 25th and 75th percentiles. We used percentiles in-
stead of standard deviations, as these better represent the distri-
bution of the data. Cost ratios were calculated by dividing the
mean health care costs of patients by the mean costs of matched
controls. Moreover, we calculated the percentage of users per
group that incurred costs for care in that specific cost category.
Statistical analyses were performed using SAS, version 9.4 (SAS
Institute, Cary, NC, USA).
RESULTS
Baseline characteristics
We identified 18 340 patients with CKD Stage G4/G5 not on
RRT, 4474 dialysis patients and 9260 patients with a function-
ing kidney transplant (Table 1). Eight percent of these trans-
plant patients were in the first year of transplantation, leaving
92% of patients who were in later years after a successful trans-
plantation. Of CKD Stage G4/G5 patients not on RRT, 2% were
categorized as young, 14% as middle-aged, 26% as elderly and
59% as 75 years. In dialysis patients, these were 7, 26, 26 and
41% and in transplant patients 21, 48, 25 and 6%, respectively.
In all age groups, more than half of the patients were men. The
median SES scores were similar. The matching was successful
with respect to age and sex (Table 1).
Total health care costs
Average annual costs and cost ratios. Figure 1 shows aver-
age annual costs for all three patient groups per age category
and the cost ratios between patients and their controls. Total
health care costs of dialysis patients were higher than those of
CKD Stage G4/G5 or transplant patients (Figure 1). Overall, the
costs of patients 75 years of age were lower than the costs of
patients 65–74 years of age, the age category with the highest
costs. In dialysis patients, costs were highest in the middle-aged
patients. Costs for patients on peritoneal dialysis were lower
than for haemodialysis patients in all age groups (Supplementary
data, Figure S1a).
Young CKD Stage G4/G5 patients had 7.6 times higher costs
than controls, whereas costs were 2.2 times higher in patients
75 years of age (Figure 1). Young dialysis patients had 69.1
times higher costs than controls and this cost ratio decreased to
15.9 in the oldest patients. Costs of young transplant patients
were 12.4 times higher than controls, decreasing to 3.4 in
patients75 years of age.
Costs per segment of health care. Total health care costs
can be differentiated in six main segments of health care [i.e.
primary care, specialist care delivered in the hospital (inpatient
and outpatient), mental health care, prescription medication,
transportation and other costs] (Supplementary data, Table
S2a–c). Young CKD patients had 9.9 times higher medication
costs than controls, which decreased to 2.7 in patients
75 years of age. Medication costs of young dialysis patients
were 56.2 times higher than those of controls and decreased to
4.9 in patients 75 years of age. In transplantation patients,
medications costs were 43.0 times higher in young patients and
6.6 times higher in the oldest patients compared with controls.
Hospital costs related to the treatment of CKD
Average annual costs. Approximately 80% of total health
care costs of dialysis patients were related to renal treatment,
and this was 10% for CKD Stage G4/G5 and roughly 20% for
transplantation (Supplementary data, Figure S2). Costs for
CKD Stage G4/G5 patients ranged from e1045 in patients
75 years of age to e1191 in middle-aged patients. In both dial-
ysis and transplant patients, costs were highest in young
patients (e70 682 and e5223, respectively) and lowest in
patients75 years of age (e66 306 and e3 838, respectively).
Hospital costs unrelated to the treatment of CKD
Average annual costs and cost ratios. Hospital costs unre-
lated to renal treatment in dialysis patients were higher than
those in controls, in particular in middle-aged dialysis patients
(e10 989 versus e1272) (Figure 2). At 13.0, the cost ratio was
highest in young dialysis patients, declining to 2.6 in patients
75 years of age. Costs for peritoneal dialysis patients were
lower than costs for haemodialysis patients in all age groups
(Supplementary data, Figure S1b). The decrease in cost ratios
with age was similar for both dialysis modalities. Also in CKD
Stage G4/G5 and transplant patients, these costs were markedly
higher than those in controls, and the cost ratios, again, showed
that this is especially true at younger age. In CKD Stage G4/G5
patients, cost ratios decreased with age from 8.1 to 2.1, compa-
rable to transplant patients, in whom cost ratios declined from
7.1 to 2.5.
Percentage health care users. In CKD Stage G4/G5
patients, as well as in transplant recipients, hospital costs unre-
lated to treatment of CKD were already substantial at a young
age (e4020 and e4181, respectively) (Figure 2). More than 70%
of these young patients used this care compared with only 30%
of young controls. In CKD Stage G4/G5 patients 75 years of
age, 89% used hospital care unrelated to treatment of CKD and
92% of transplant patients 75 years of age used hospital care
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unrelated to treatment compared with 70% of controls.
Remarkably, 88% of young dialysis patients needed additional
hospital care versus 31% of controls. This increased to 93% in
the oldest dialysis patients compared with 73% of controls.
Annual health care costs and health care utilization per
medical specialty
Figures 3a and b and Supplementary data, Figure S3a and b,
show that CKD Stage G4/G5, dialysis and kidney transplant
patients had 1.5–93.4 times higher costs related to care of inter-
nal medicine, cardiologists, dermatologists and surgeons. In
all categories, cost ratios were high in young patients and de-
creased with age.
Internal medicine. Almost 40% of all CKD Stage G4/G5
patients needed internal medicine care (Figure 3a). In young di-
alysis patients, 43% received internal medicine care, increasing
to 50% in elderly patients. In dialysis patients 75 years of
age, this was 44%. This proportion was 27% in young transplant
patients and increased with age. Regardless of age, most resources
were spent on care related to diabetes mellitus and infectious dis-
eases (i.e. sepsis/bacteraemia and pneumonia) (Supplementary
data, Table S3a). In controls, diabetes mellitus–related care was
also the major part of internal medicine care. In addition, the ma-
jority of claims in the elderly controls were related to oncology
care (breast cancer).
Cardiology. A total of 43% of young dialysis patients needed
cardiology care compared with 2% of controls (Figure 3b). This
increased to 54 and 58% inmiddle-aged and elderly patients, re-
spectively, compared with 8 and 16% in controls, respectively.
With 15 and 11% use of cardiology care in young CKD Stage
G4/G5 and transplantation patients, respectively, this was sub-
stantially higher than controls (2%). Almost half of all CKD
Stage G4/G5 patients 75 years of age visited a cardiologist at
least once a year.
Cardiology claims in patients were mostly related to ischae-
mia-related disorders (i.e. angina pectoris, acute coronary syn-
drome or follow-up after coronary angioplasty or coronary
artery bypass graft), whereas in controls the majority of cardiol-
ogy care was assigned to ischaemia-related disorders and car-
diac arrhythmia disorders (Supplementary data, Table S3b).
Dermatology. Almost one-quarter of young and more than
half of transplant recipients 75 years of age used dermatology
resources, compared with 4 and 13% of controls, respectively
(Supplementary data, Figure S3a). In CKD Stage G4/G5 and di-
alysis patients, this ranged from 7 to 25%. In all patients, the
treatment of malignant and premalignant skin lesions was the
most common reason for dermatological care; 38% of elderly
transplant patients and 45% of transplant patients 75 years of
age needed dermatological care for these reasons, compared
with only 6 and 10% of controls, respectively.
Table 1. Baseline characteristics of CKD Stage G4/G5 not on RRT, dialysis and kidney transplant patients and matched controls by age category
Age group CKD Stage G4/G5 Dialysis Kidney transplantation
Patients Controls Patients Controls Patients Controls
Age 20–44 years
n (%) 388 (2) 776 (2) 315 (7) 630 (7) 1908 (21) 3816 (21)
Age (years), median
(25th–75th percentile)
38 (32–42) 38 (32–42) 37 (31–41) 37 (31–41) 37 (30–41) 37 (30–41)
Sex (male), % 54 54 59 59 60 60
SES score, median
(25th–75th percentile)
0.3 (1.2–0.4) 0.2 (1.1–0.4) 0.6 (1.3–0.4) 0.4 (1.4–0.4) 0.2 (1.2–0.5) 0.2 (1.2–0.5)
Age 45–64 years
n (%) 2502 (14) 5004 (14) 1163 (26) 2326 (26) 4489 (48) 8978 (48)
Age (years), median
(25th–75th percentile)
59 (54–62) 59 (54–62) 57 (52–61) 57 (52–61) 55 (51–60) 55 (51–60)
Sex (male), % 52 52 59 59 60 60
SES score, median
(25th–75th percentile)
0.2 (1.1–0.5) 0.2 (1.1–0.5) 0.4 (1.4–0.3) 0.4 (1.3–0.3) 0.1 (1.0–0.6) 0.1 (1.0–0.6)
Age 65–75 years
n (%) 4705 (26) 9410 (26) 1166 (26) 2332 (26) 2267 (24) 4534 (24)
Age (years), median
(25th–75th percentile)
70 (68–72) 70 (68–72) 70 (68–72) 70 (68–72) 69 (67–71) 69 (67–71)
Sex (male), % 58 58 58 58 60 60
SES score, median
(25th–75th percentile)
0.2 (1.0–0.5) 0.2 (1.0–0.5) 0.4 (1.3–0.4) 0.4 (1.3–0.4) 0.1 (1.0–0.6) 0.1 (0.9–0.6)
Age 75 years
n (%) 10 745 (59) 21 490 (59) 1830 (41) 3660 (41) 598 (6) 1196 (6)
Age (years), median
(25th–75th percentile)
82 (78–86) 82 (78–86) 81 (78–84) 81 (78–84) 77 (76–79) 77 (76–79)
Sex (male), % 53 53 58 58 60 60
SES score, median
(25th–75th percentile)
0.2 (1.0–0.4) 0.2 (1.0–0.5) 0.2 (1.1–0.4) 0.2 (1.1–0.4) 0.1 (1.0–0.5) 0.1 (1.0–0.5)
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Surgery. Twenty-nine percent of young dialysis patients
and 40% of elderly patients needed surgical care versus 5 and
12% of controls, respectively (Supplementary data, Figure S3b).
In the oldest dialysis patients, this was 35%. For both CKD
Stage G4/G5 and transplant patients, surgery costs were lower
for patients 75 years of age than for patients 65–74 years
of age.
In general, surgical care was mainly related to vascular disor-
ders like peripheral arterial occlusive disease, ischaemic ulcers
and diabetic foot ulcers (Supplementary data, Table S3d).
Approximately 8% of elderly dialysis patients needed surgical
care for peripheral arterial occlusive disease, more than elderly
CKD Stage G4/G5 patients (5%) or elderly transplant patients
(3%). Surgical care in controls was related to a wider variety of
conditions, such as malignancies (breast cancer), abdominal
aortic aneurysm or inguinal or femoral hernia.
DISCUSSION
In this study we describe for the first time the age-related differ-
ences in health care costs and health care use in CKD Stage G4/
G5 not on RRT, dialysis and kidney transplant patients com-
pared with matched controls from the general Dutch population.
As is already known, RRT is expensive; in our study, annual
treatment-related costs for CKD patients ranged from e1045 in
CKD Stage G4/G5 patients 75 years of age to e70 682 in
young dialysis patients. However, the additional hospital costs
unrelated to CKD treatment ranged from e4020 (young CKD
Stage G4/G5 patients) to e10 989 (middle-aged dialysis
patients), whereas these hospital costs in the control population
ranged from e497 to e3065.
Regarding age differences, in controls, health care costs in-
creased gradually with age. This contrasts with our three patient
groups, where costs were often equivalent in different age
FIGURE 1: Total annual health care costs of CKD Stage G4/G5 not on RRT, dialysis and kidney transplant patients versus matched controls.
*Denotes the percentage of users per group that incurred costs for care in that speciﬁc cost category.
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categories or young and middle-aged patients were more costly
than elderly patients. Of note, costs for CKD Stage G4/G5 and
dialysis patients 75 years of age were lower than for patients
65–74 years of age. We further demonstrated that young
patients in particular incur considerably higher costs than con-
trols, which is reflected by the decreasing cost ratios with age.
Furthermore, we showed that renal patients were in greater
need of additional specialist care because of kidney disease–
related comorbidities. Although it is known that the burden of
comorbidities is higher in elderly CKD patients, this study
shows that costs related to comorbid illness in young patients is
similar to that of elderly patients.
Age-related difference of health care costs in CKD
patients
We demonstrated that health care costs for renal patients
did not differ as much with age as in the general population.
Several studies have shown rising health care costs with age in
the general population [14–16], whereas studies in CKD and
RRT patients have shown no consistent effect of age on health
care costs [17–19]. An interesting finding in our study is that
the annual health care costs of CKD Stage G4/G5 and dialysis
patients 75 years of age were lower than for patients 65–
74 years of age. This is mainly driven by a decrease in hospital
and medication costs with age. An explanation for this observa-
tion can possibly be found in the fact that a nephrologist deter-
mines for every patient the need for a specific treatment or
diagnostic procedure. This thoughtful weighing of harms and
benefits may result in different outcomes in the geriatric pa-
tient, leading to more conservative treatment options and thus
a lowering of total health care expenses.
Our study shows that a comparison of costs within the general
population is essential to fully understand the additional costs of
kidney patients in different age categories. Only two studies have
FIGURE 2: Hospital costs unrelated to treatment of CKD Stage G4/G5 not on RRT, dialysis and kidney transplant patients versus hospital
costs of matched controls. *Denotes the percentage of users per group that incurred costs for care in that speciﬁc cost category.
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FIGURE 3: Annual health care costs of CKD Stage G4/G5 not on RRT, dialysis and kidney transplant patients per medical specialty versus
matched controls. (a) Internal medicine. (b) Cardiology. *Denotes the percentage of users per group that incurred costs for care in that speciﬁc
cost category.
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presented costs of CKD and RRT patients compared with those
of matched controls in the general population, and none of these
took age into account. One study from the US focusing on
patients with CKD Stage G2–G4 found that the total health care
costs of patients were twice as high compared with those of
matched controls [20]. This study was based on aggregated cost
data from 2001. Another paper compared costs of CKD Stage
G4/G5 not on RRT, dialysis and kidney transplant patients with
matched controls using a population-based cohort in Sweden
[21]. The study populations in that study are comparable to ours
and the described mean annual costs of CKD, dialysis and trans-
plant patients are in line with our results. Although an analysis of
different age categories is missing, the cost ratios of the Swedish
study are similar to those in middle-aged patients in our study.
Extremely high cost ratios in young patients were not described.
Costs and utilization of additional hospital care
In this study we discriminated between treatment-related
and non-treatment-related hospital costs. Non-treatment-re-
lated hospital costs are a good measure of patients’ comorbid-
ities since they reflect the additional hospital care needed apart
from treatment of the kidney disease [19, 22]. It is well-known
that patients in different stages of CKD suffer from comorbid-
ities with a significant financial impact [9, 23]. In our study,
80% of total hospital costs in CKD Stage G4/G5 patients were
unrelated to specific renal treatment. In transplant patients, this
varied between 48% and 71% across age categories, whereas in
dialysis patients only 10–14% of hospital costs were unrelated
to treatment. This effect is far more pronounced in young than
in elderly renal patients (all modalities). These results show that
the majority of renal patients need substantially more addi-
tional hospital care apart from their renal treatment, reflecting a
high prevalence of comorbidities already at a young age.
Specialized care for CKD-related comorbidities
Not only the costs of additional specialist care in renal
patients are higher than those in controls, also the diagnoses un-
derlying these costs are different. We showed that a significant
number of renal patients need cardiology care and this propor-
tion increases with age. We also showed that cardiology resour-
ces of renal patients are mainly directed to ischaemia-related
diseases, whereas controls from the general population are more
often affected with cardiac arrhythmias. Regarding surgery,
resources for patients turned out to be predominantly used in
care related to vascular disorders, whereas health care use in con-
trols is more often related to malignant diseases. These results
confirm that renal patients are frequently affected by cardiovas-
cular complications, which are associated with higher costs [22].
Previous research revealed that CKD patients with diabetes
have higher costs [18, 19]. This is in line with our study, which
also shows that renal patients have relatively high costs for in-
ternal medicine care and most resources were spent on
diabetes-related care. In addition, infectious diseases–related
care was shown to be frequent in renal patients. In dermatology
care, we observed that with age, transplant patients increasingly
suffer from malignant and premalignant skin lesions. This is
consistent with literature showing that not only elderly patients,
but also long-term survivors after kidney transplantation have a
higher incidence of skin malignancies associated with the use of
immunosuppressive drugs [24].
Strengths and limitations
The main strength of our study is the use of a health care
claims database with nationwide coverage. This enabled us to
identify all CKD Stage G4/G5 not on RRT, dialysis and kidney
transplant patients in the Netherlands treated in the hospital with
an insurance health claim. The database also provided a unique
opportunity to select matched controls from the general popula-
tion. The comprehensiveness of the cost data allowed for an analy-
sis of health care costs beyond the direct renal treatment costs.
A general limitation of studying costs with the use of health
care claims data is that health care expenditures may not reflect
the actual costs, since expenditures are actually negotiated prices
between health insurance companies and caregivers. Another lim-
itation is the accuracy of the identification of patients with the use
of health care claims data. Although identification of patients on
RRT was shown to be very accurate [25], the identification of
patients with advanced CKD using claims data is subject to under-
identification, as we could only select patients actively treated for
CKD in a hospital (including outpatient clinics). As a conse-
quence, CKD patients solely treated in primary care could not be
identified with claims data. Next, the SES score used for the
matching of patients with controls is based on a persons’ postal
code and may not reflect the true SES of the individual. Next, by
excluding patients who died during the study year and patients
starting dialysis treatment, we did not report end-of-life costs and
costs related to the start of dialysis treatment. Finally, by including
newly transplanted patients during the study year, as health care
costs are given per calendar year in this database, this results in an
inaccurate estimation of true transplantation procedure costs.
However, the costs before transplantation still reflect the costs of a
CKD patient preparing for transplantation therapy.
CONCLUSION
In conclusion, this study found that CKD Stage G4/G5 not on
RRT, dialysis and kidney transplant patients have notably
higher health care costs than the general population. We show
for the first time that, already at a young age, additional health
care costs of CKD patients are significantly higher than the
health care costs of people of the same age in the general popu-
lation. Additionally, we demonstrate that non-treatment-re-
lated hospital costs of CKD Stage G4/G5 patients not on RRT
are similar to those of transplant patients in all age groups, al-
though markedly lower than in dialysis patients. This indicates
that at young age and in earlier stages of CKD, patients are in
need of additional care far exceeding the needs of people in the
general population. While total health care costs for the general
population continue to increase with age, we observe a decrease
in costs in all patient groups 75 years of age, which is largely
explained by a decrease in hospital and medication costs.
This study provides insight into the specific diagnoses for
which patients need additional hospital care. This knowledge of
the specific use of hospital resources reveals that the consequen-
ces of the comorbidity burden in renal patients are already
8 M.J.M. van Oosten et al.
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present at a young age, which supports the importance of age-
specific management of CKD patients aimed at prevention and
early treatment of comorbid diseases.
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